To critically assess available high-level clinical studies regarding RBC transfusion strategies, with a focus on hemoglobin transfusion thresholds in the ICU.
Source data were obtained from a PubMed literature review.
English language studies addressing RBC transfusions in the ICU with a focus on the most recent relevant studies.
Relevant studies were reviewed and the following aspects of each study were identified, abstracted, and analyzed: study design, methods, results, and implications for critical care practice.
Approximately 30–50% of ICU patients receive a transfusion during their hospitalization with anemia being the indication for 75% of transfusions. A significant body of clinical research evidence supports using a restrictive transfusion strategy (e.g., hemoglobin threshold < 7 g/dL) compared with a more liberal approach (e.g., hemoglobin threshold < 10 g/dL). A restrictive strategy (hemoglobin < 7 g/dL) is recommended in patients with sepsis and gastrointestinal bleeds. A slightly higher restrictive threshold is recommended in cardiac surgery (hemoglobin < 7.5 g/dL) and stable cardiovascular disease (hemoglobin < 8 g/dL). Although restrictive strategies are generally supported in hematologic malignancies, acute neurologic injury, and burns, more definitive studies are needed, including acute coronary syndrome. Massive transfusion protocols are the mainstay of treatment for hemorrhagic shock; however, the exact RBC to fresh frozen plasma ratio is still unclear. There are also emerging complimentary practices including nontransfusion strategies to avoid and treat anemia and the reemergence of whole blood transfusion.
The current literature supports the use of restrictive transfusion strategies in the majority of critically ill populations. Continued studies of optimal transfusion strategies in various patient populations, coupled with the integration of novel complementary ICU practices, will continue to enhance our ability to treat critically ill patients.
1Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
2Department of Surgery, Emory University School of Medicine, Atlanta, GA.
3Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
New affiliation for Dr. Cable: Division of Pulmonary Diseases and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.
Drs. Cable and Murphy received support for article research from the National Institutes of Health (NIH). Dr. Cable’s institution received funding from NIH/National Institute of General Medical Sciences T32 GM-095442. Dr. Roback’s institution received funding from the NIH and Zipline Medical, and he received funding from CSL Plasma and Castle Medical. Dr. Murphy’s institution received funding from the NIH. Dr. Razavi disclosed that he does not have any potential conflicts of interest.
For information regarding this article, E-mail: email@example.com